FDA, USPTO In Middle Of Congressional Tug-Of-War Over Patents And Drug Pricing
Executive Summary
Senators Hassan and Cassidy contend the lack of coordination between the two agencies may allow patent thickets to grow. Meanwhile, Sen. Tillis is pushing the agency to refute data alleging patents are to blame for high drug prices.
You may also be interested in...
US FDA, PTO Pulled Into Debate Over Patents And Drug Pricing
Senator Tillis requests the two agencies conduct an independent analysis of I-MAK data and the ‘false narrative’ that patents are to blame for high drug prices.
Generic Entry Reforms Gain Steam In Congress With House Committee Passage
Bills to reign in petitions, pay-for-delay, product hopping, and patent thickets clear House Judiciary Committee. Legislation may have better shot at enactment this time around given bipartisan support in both House and Senate Committees.
US FDA’s Patent ‘Concerns’ Include Thickets, Product Hopping, And Evergreening
Senators press for sharing of FDA applications with PTO as Woodcock letter seeks collaboration on everything from PTAB to patent term extensions to ‘possible misuse of the patent system.’